- Home
- CLB vs APLT Comparison
CLB vs APLT Comparison
Compare CLB & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLB
- APLT
- Stock Information
- Founded
- CLB 1936
- APLT 2016
- Country
- CLB United States
- APLT United States
- Employees
- CLB N/A
- APLT N/A
- Industry
- CLB
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- CLB
- APLT Health Care
- Exchange
- CLB Nasdaq
- APLT Nasdaq
- Market Cap
- CLB 951.4M
- APLT 971.6M
- IPO Year
- CLB 1995
- APLT 2019
- Fundamental
- Price
- CLB $19.50
- APLT $8.69
- Analyst Decision
- CLB Sell
- APLT Strong Buy
- Analyst Count
- CLB 4
- APLT 5
- Target Price
- CLB $17.00
- APLT $12.50
- AVG Volume (30 Days)
- CLB 344.3K
- APLT 1.8M
- Earning Date
- CLB 10-23-2024
- APLT 11-07-2024
- Dividend Yield
- CLB 0.20%
- APLT N/A
- EPS Growth
- CLB N/A
- APLT N/A
- EPS
- CLB 0.54
- APLT N/A
- Revenue
- CLB $522,821,000.00
- APLT N/A
- Revenue This Year
- CLB $4.59
- APLT N/A
- Revenue Next Year
- CLB $5.11
- APLT $3,169.03
- P/E Ratio
- CLB $36.15
- APLT N/A
- Revenue Growth
- CLB 2.68
- APLT N/A
- 52 Week Low
- CLB $13.82
- APLT $1.79
- 52 Week High
- CLB $25.13
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- CLB 49.03
- APLT 46.34
- Support Level
- CLB $20.41
- APLT $9.44
- Resistance Level
- CLB $21.65
- APLT $10.62
- Average True Range (ATR)
- CLB 0.73
- APLT 0.62
- MACD
- CLB -0.01
- APLT -0.13
- Stochastic Oscillator
- CLB 24.45
- APLT 14.95
About CLB Core Laboratories Inc.
Core Laboratories is the premier provider of reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.